An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder
The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Memantine
Ages Eligible For Study:
- at least 18 years of age - suffering from OCD - Y-BOCS score of 18 or greater - taking a therapeutic dose of an anti-OCD medication specified in the protocol